Dennis D. Kim

Dennis D.
Kim is President & Chief Executive Officer at Xeno Biosciences, Inc. Former positions include Executive Director-Strategy at Amylin Pharmaceuticals, Inc. from 2001 to 2007; Independent Director at Inversago Pharma, Inc. from 2019 to 2022; Chief Medical Officer at CymaBay Therapeutics, Inc. from 2021 to 2023; Senior VP-Medical Affairs & Communications at Orexigen Therapeutics, Inc. from 2010 to 2011; Chief Medical Officer at Zafgen, Inc. from 2011 to 2019; Chief Medical Officer at Cebix, Inc.; Assistant Professor at the University of California San Diego from 2001 to 2012; Chief Medical Officer & VP-Medical Affairs at EnteroMedics, Inc. from 2007 to 2008; Chief Medical Officer at Skye Bioscience, Inc. from 2019 to 2020; Chief Medical Officer at Emerald Health Sciences, Inc.; and Chief Medical Officer at AFYX Therapeutics AS.
Education includes a doctorate from Finch University of Health Sciences, an undergraduate degree from the University of California, Los Angeles, an MBA from Rady School of Management at UC San Diego, and a doctorate from Chicago Medical School.